Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction

Prof. Dr. Marc-H. Dahlke, Ph. D.

Status: Unknown

Conditions: Multiple Organ Failure; Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT02426645

Mibisep

Details and patient eligibility

About

The aim of this study is to investigate associations between early structural cellular injury and microvascular alteration with progression of septic organ dysfunction according to total SOFA-Score (an ICU-scoring system - the Sequential Organ Failure Assessment Score). Patients will be monitored for renal (TIMP-2, IGFBP7), and intestinal biomarkers (plasma i-FABP) in conjunction with kidney and muscle vascular bed microvascular perfusion analysis assessed by contrast-enhanced ultrasonography (CEUS). In parallel, a comprehensive analysis of patients' immunological status will be conducted using an established, on-site immune monitoring panel.

The ultimate goal of this study is an early identification of septic patients developing multiorgan dysfunction which may facilitate a timely novel intervention in the future to improve outcome.

Enrollment: 25 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients ≥18 years of age with severe sepsis and fulfill the following criteria at the admission to ICU:

• Peritonitis (abdominal infection) and performed source control (either surgically or interventionally)
• 2 or more criteria for systemic inflammatory response syndrome (temperature >38° or<36°; heart rate >90 beats per minute; respiratory rate >20 breaths per minute or paCO2 <32 mmHg; white blood cell count >12,000/mm3, <4000mm3 or >10% immature forms) and serum lactate level of 4mmol/l and more or refractory hypotension - mean arterial pressure <65mmHg or systolic blood pressure <90mmHg after fluid challenge of 1000ml or more /30min
• Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• Written informed consent prior to any study procedures

Exclusion criteria

• Pre-existing renal-replacement therapy in the pre-operative course
• Pre-existing shock
• Acute coronary syndrome
• Active hemorrhage
• Trauma
• Known allergy to ultrasound contrast media
• Anemia with hemoglobin concentration < 7g/dl
• Patients not able to give written informed consent